Статті в журналах з теми "Cytokines; T315I mutation; chronic myeloid leukaemia"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-37 статей у журналах для дослідження на тему "Cytokines; T315I mutation; chronic myeloid leukaemia".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Asari, Kartini, Susan L. Heatley, Teresa Sadras, Tamara M. Leclercq, Stephen Fitter, Chung Hoow Kok, Andrew C. W. Zannettino, Timothy P. Hughes, and Deborah L. White. "In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy." Blood 128, no. 22 (December 2, 2016): 3957. http://dx.doi.org/10.1182/blood.v128.22.3957.3957.
Повний текст джерелаHughes, Tim, and Giuseppe Saglio. "Expert Opinion on the Treatment of Refractory Chronic Phase Chronic Myeloid Leukaemia." European Oncology & Haematology 13, no. 01 (2017): 17. http://dx.doi.org/10.17925/eoh.2017.13.01.17.
Повний текст джерелаMassaro, Fulvio, Matteo Molica, and Massimo Breccia. "Ponatinib: A Review of Efficacy and Safety." Current Cancer Drug Targets 18, no. 9 (October 17, 2018): 847–56. http://dx.doi.org/10.2174/1568009617666171002142659.
Повний текст джерелаO’Connor, Lisa M., Stephen Langabeer, Shaun R. McCann, and Eibhlin Conneally. "BCR-ABL Kinase Domain Mutations & SNPs in Imatinib Resistant or Intolerant Chronic Myeloid Leukaemia Patients." Blood 110, no. 11 (November 16, 2007): 2369. http://dx.doi.org/10.1182/blood.v110.11.2369.2369.
Повний текст джерелаJørgensen, H. G., and T. L. Holyoake. "Characterization of cancer stem cells in chronic myeloid leukaemia." Biochemical Society Transactions 35, no. 5 (October 25, 2007): 1347–51. http://dx.doi.org/10.1042/bst0351347.
Повний текст джерелаKhorashad, J. S., N. Thelwell, D. Milojkovic, D. Marin, J. A. Watson, J. M. Goldman, J. F. Apperley, L. Foroni, and A. G. Reid. "A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia." Journal of Clinical Pathology 61, no. 7 (April 22, 2008): 863–65. http://dx.doi.org/10.1136/jcp.2008.056804.
Повний текст джерелаGutierrez, J. Valentin Garcia, Jesùs Odriozola, Javier Lopez, Pilar Herrera, Maria Calbacho, Marta Jimenez-Rolando, Maria Tenorio, Anabelle Chinea, and Jose Garcia-Laraña. "Detection of BCR-ABL Mutations in Patients with Chronic Myeloid Leukemia Treated with Imatinib. Experience of One Centre." Blood 114, no. 22 (November 20, 2009): 4280. http://dx.doi.org/10.1182/blood.v114.22.4280.4280.
Повний текст джерелаVráblová, Lucia, Vladimír Divoký, Pavla Kořalková, Kateřina Machová Poláková, Eva Kriegová, Romana Janská, Jan Grohmann, Milena Holzerová, Tomáš Papajík та Edgar Faber. "Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia". International Journal of Molecular Sciences 24, № 3 (20 січня 2023): 2050. http://dx.doi.org/10.3390/ijms24032050.
Повний текст джерелаPelz-Ackermann, Oliver, Michael W. Deininger, Michael Cross, Ines Kovacs, Christine Guenther, Knuth Krohn, Song-Yau Wang, Haifa K. Al-Ali, Dietger W. Niederwieser, and Thoralf Lange. "First Results of a New PCR-Based Approach for a Sensitive and Quantitative Monitoring of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia." Blood 108, no. 11 (November 1, 2006): 2191. http://dx.doi.org/10.1182/blood.v108.11.2191.2191.
Повний текст джерелаAbruzzese, Elisabetta, Gabriella Marfe’, Carla Di Stefano, Malgorzata M. Trawinska, Matteo A. Russo, Romano Silvestri, Giovanni Del Poeta, et al. "Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib, Nilotinib) Resistant." Blood 108, no. 11 (November 16, 2006): 1385. http://dx.doi.org/10.1182/blood.v108.11.1385.1385.
Повний текст джерелаConnor, Lisa M. O’, Stephen Langabeer, Shaun R. McCann, and Eibhlin Conneally. "Mutation Mediated Resistance to the Tyrosine Kinase Inhibitors Imatinib, Dasatinib & Nilotinib in Philadelphia Positive Leukaemia." Blood 112, no. 11 (November 16, 2008): 4245. http://dx.doi.org/10.1182/blood.v112.11.4245.4245.
Повний текст джерелаCoude, Marie-Magdelaine, Odile Luycx, Marie-Estelle Cariou, Odile Maarek, Hervé Dombret, Jean-Michel Cayuela, and Delphine Rea. "Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation." British Journal of Haematology 157, no. 3 (January 9, 2012): 407–10. http://dx.doi.org/10.1111/j.1365-2141.2011.09016.x.
Повний текст джерелаKim, Soo-Hyun, Dongho Kim, Dong-Wook Kim, Hyun-Gyung Goh, Se-Eun Jang, Jeong Lee, Wan-Seok Kim, Il-Young Kweon, and Sa-Hee Park. "Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent." Hematological Oncology 27, no. 4 (December 2009): 190–97. http://dx.doi.org/10.1002/hon.894.
Повний текст джерелаCopland, Mhairi, Daniel Slade, Jenny Byrne, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard Clark, et al. "FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial." Blood 134, Supplement_1 (November 13, 2019): 497. http://dx.doi.org/10.1182/blood-2019-125591.
Повний текст джерелаPelz-Ackermann, Oliver, Michael W. N. Deininger, Michael Cross, Kathrin Wildenberger, Rainer Krahl, Song-Yau Wang, Haifa K. Al-Ali, Dietger W. Niederwieser, and Thoralf Lange. "BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses." Blood 110, no. 11 (November 16, 2007): 2918. http://dx.doi.org/10.1182/blood.v110.11.2918.2918.
Повний текст джерелаCea, Michele, Antonia Cagnetta, Gabriella Cirmena, Anna Garuti, Ilaria Rocco, Claudia Palermo, Ivana Pierri, et al. "Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment." Blood 116, no. 21 (November 19, 2010): 1215. http://dx.doi.org/10.1182/blood.v116.21.1215.1215.
Повний текст джерелаCerveira, N., R. B. Ferreira, S. Bizarro, C. Correira, L. Torres, S. Lisboa, J. Vieira, et al. "PB1922 PONATINIB INDUCES A SUSTAINED DEEP MOLECULAR RESPONSE IN A CHRONIC MYELOID LEUKAEMIA PATIENT WITH AN EARLY RELAPSE WITH A T315I MUTATION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION." HemaSphere 3, S1 (June 2019): 874. http://dx.doi.org/10.1097/01.hs9.0000566188.04988.71.
Повний текст джерелаIbrahim, Amr R., Marco Bua, Jamshid S. Khorshad, Dragana Milojkovic, Lina Eliasson, Richard Szydlo, Letizia Foroni, et al. "Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs." Blood 116, no. 21 (November 19, 2010): 2274. http://dx.doi.org/10.1182/blood.v116.21.2274.2274.
Повний текст джерелаKaeda, Jaspal S., Ken I. Mills, Michael G. Kharas, Giuseppe Saglio, Michaela Schwarz, Christian Oberender, Bärbel Pawlaczyk-Peter, et al. "Increased MSI2 expression Is Associated with Aggressive CML and AML." Blood 118, no. 21 (November 18, 2011): 2516. http://dx.doi.org/10.1182/blood.v118.21.2516.2516.
Повний текст джерелаBenedicte, Deau, Bachy Emmanuel, Raus Nicole, Nicolini Franck-emmanuel, Rea Delphine, Reman Oumedaly, Maillard Natacha, et al. "Impact of Prior Second-Generation Tyrosine Kinase Inhibitors on the Outcome of Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia." Blood 116, no. 21 (November 19, 2010): 2267. http://dx.doi.org/10.1182/blood.v116.21.2267.2267.
Повний текст джерелаVannuffel, Pascal, Barbara Cauwelier, Céline De Rop, and Friedel Nollet. "Detection and Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing." Blood 126, no. 23 (December 3, 2015): 4042. http://dx.doi.org/10.1182/blood.v126.23.4042.4042.
Повний текст джерелаHayakawa, Fumihiko, Keiki Sugimoto, Shingo Kurahashi, Hironori Matsuyama, Yasuo Harada, Norikazu Hashimoto, Naoto Ohi, et al. "A Novel Direct STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition In a Wide Range of Hematopoietic Malignancies and Effectively Suppresses the Chemotherapy Resistant Quiescent Cells In Vivo." Blood 116, no. 21 (November 19, 2010): 3277. http://dx.doi.org/10.1182/blood.v116.21.3277.3277.
Повний текст джерелаCilloni, Daniela, Francesca Messa, Roberto Bernardoni, Francesca Arruga, Monica Pradotto, Enrico Bracco, Cristina Panuzzo, et al. "Identification of Genes Sustaining Bcr-Abl Oncogenic Signalling and CML Progression through a Genetic Tool Based on Human Bcr-Abl Transgenic Drosophila Melanogaster." Blood 112, no. 11 (November 16, 2008): 1091. http://dx.doi.org/10.1182/blood.v112.11.1091.1091.
Повний текст джерелаZhang, Xiaoshuai, Zongru Li, Yazhen Qin, Robert Peter Gale, Xiaojun Huang, and Qian Jiang. "Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy." Blood 138, Supplement 1 (November 5, 2021): 308. http://dx.doi.org/10.1182/blood-2021-150020.
Повний текст джерелаJiang, Xiaoyan, Hannah Grant, Justin Stebbing, Letizia Foroni, Charles Craddock, Mike Griffiths, Richard E. Clark, et al. "Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype." Blood 116, no. 21 (November 19, 2010): 3397. http://dx.doi.org/10.1182/blood.v116.21.3397.3397.
Повний текст джерелаRossi, Davide, Clara Deambrogi, Tiziana Lischetti, Michaela Cerri, Marianna Spunton, Silvia Rasi, Silvia Franceschetti, et al. "Hypermethylation of SH2-Containing Phosphatase-1 (SHP-1) and Suppressor of Cytokine Signaling-1 and -3 (SOCS-1 and -3) in Philadelphia Negative Chronic Myeloproliferative Disorders (Ph-CMPD)." Blood 108, no. 11 (November 16, 2006): 118. http://dx.doi.org/10.1182/blood.v108.11.118.118.
Повний текст джерелаCilloni, Daniela, Francesca Messa, Francesca Arruga, Enrico Bracco, Paolo Nicoli, Emanuela Messa, Stefano Ulisciani, et al. "Development of a Genetic Tool Based on BCR-ABL Transgenic Drosophila Melanogaster for Identification of Genes Involved in CML Progression and Drug Testing." Blood 110, no. 11 (November 16, 2007): 468. http://dx.doi.org/10.1182/blood.v110.11.468.468.
Повний текст джерелаCopland, Mhairi, Ashley Hamilton, Janet W. Baird, Martin Barow, Elaine K. Allan, Lucy J. Elrick, and Tessa L. Holyoake. "Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro, but Does Not Eradicate Quiescent CML Stem Cells." Blood 106, no. 11 (November 16, 2005): 695. http://dx.doi.org/10.1182/blood.v106.11.695.695.
Повний текст джерелаÅgerstam, Helena, Nils Hansen, Sofia Von Palffy, Carl Sandén, Kristian Reckzeh, Christine Karlsson, Henrik Lilljebjörn, et al. "IL1RAP Antibodies Block IL1-Induced Expansion of Primitive CML Cells and Display Therapeutic Effects in Xenograft Models." Blood 128, no. 22 (December 2, 2016): 1118. http://dx.doi.org/10.1182/blood.v128.22.1118.1118.
Повний текст джерелаTschiedel, Sabine, Melanie Adler, Tobias Dietrich, Michael Cross, Vladan Vucinic, and Dietger Niederwieser. "Peptides from Nme2 Are Preferentially Expressed By Chronic Phase CML Cells, Recognized By T Cells and Restricted By the Most Frequent HLA-Antigens." Blood 124, no. 21 (December 6, 2014): 4511. http://dx.doi.org/10.1182/blood.v124.21.4511.4511.
Повний текст джерелаDe Lavallade, Hugues, Sophie Jackson, Heather Oakervee, Sebastian Francis, Edward Belsham, Paul Cahalin, Joanne Ewing, et al. "Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy." Blood 134, Supplement_1 (November 13, 2019): 2935. http://dx.doi.org/10.1182/blood-2019-129825.
Повний текст джерелаTraer, Elie, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer B. Dunlap, Isabel English, Jacqueline Martinez, Jeffrey W. Tyner, Melissa Wong, and Brian J. Druker. "FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib." Blood 122, no. 21 (November 15, 2013): 3983. http://dx.doi.org/10.1182/blood.v122.21.3983.3983.
Повний текст джерелаClaudiani, Simone, Jane Apperley, Afzal Khan, Richard Szydlo, George Nesr, George Adams, Letizia Foroni, Jamshid S. Khorashad, and Dragana Milojkovic. "Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients." Blood 132, Supplement 1 (November 29, 2018): 3007. http://dx.doi.org/10.1182/blood-2018-99-119602.
Повний текст джерелаYeung, David T., Michael Philip Osborn, Deborah L. White, Susan Branford, Michael Kornhauser, Cassandra Slader, Samar Issa, et al. "Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial." Blood 120, no. 21 (November 16, 2012): 3771. http://dx.doi.org/10.1182/blood.v120.21.3771.3771.
Повний текст джерелаG. Lindström, H. Jonathan, and Ran Friedman. "The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib." BMC Cancer 20, no. 1 (May 7, 2020). http://dx.doi.org/10.1186/s12885-020-06782-9.
Повний текст джерелаKim, Wan-Seok, Dongho Kim, Dong-Wook Kim, Il-Young Kweon, Soo-Hyun Kim, Hyun-Gyung Goh, Sa-Hee Park, and Jeong Lee. "Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors." Hematological Oncology, 2009, n/a. http://dx.doi.org/10.1002/hon.918.
Повний текст джерелаCerveira, Nuno, Rosa Branca Ferreira, Susana Bizarro, Cecília Correia, Lurdes Torres, Susana Lisboa, Joana Vieira, et al. "Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report." BMC Cancer 18, no. 1 (December 2018). http://dx.doi.org/10.1186/s12885-018-5100-4.
Повний текст джерела